Bristol-Myers Squibb Profit Margins 2006-2018 | BMY

Current and historical gross, operating and net profit margins for Bristol-Myers Squibb (BMY) over the last 10 years. The current net profit margin for Bristol-Myers Squibb as of June 30, 2018 is 1.74%.
Bristol-Myers Squibb Annual Profit Margin Summary
Bristol-Myers Squibb Quarterly Profit Margin Summary
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $96.944B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $350.789B 16.76
Pfizer (PFE) United States $243.651B 14.26
Novartis AG (NVS) Switzerland $190.263B 16.32
Merck (MRK) United States $178.137B 15.73
AbbVie (ABBV) United States $145.067B 14.17
Novo Nordisk (NVO) Denmark $114.528B 18.31
Eli Lilly (LLY) United States $109.815B 20.33
Sanofi (SNY) France $104.261B 13.20
AstraZeneca (AZN) United Kingdom $99.745B 10.97
GlaxoSmithKline (GSK) United Kingdom $99.569B 13.30